Clinical Trials on Refractory Malignant Solid Neoplasm in Finland

Total 229 results

National Cancer Institute (NCI)

Completed

Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

Stage III Soft Tissue Sarcoma AJCC v7 | Stage IV Soft Tissue Sarcoma AJCC v7 | Recurrent Adult Soft Tissue Sarcoma | Myxofibrosarcoma | Recurrent Leiomyosarcoma | Recurrent Malignant Peripheral Nerve Sheath Tumor | Recurrent Undifferentiated Pleomorphic Sarcoma | Recurrent Liposarcoma

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Melatonin and Radiation Therapy in Treating Patients With Brain Metastases

Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer | Radiation Toxicity

United States, Canada
AbbVie

Active, not recruiting

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

Advanced Solid Tumors Cancer | Non Small Cell Lung Cancer (NSCLC)

United States, Australia, France, Israel, Japan, Korea, Republic of, Spain, Taiwan
Novartis Pharmaceuticals

Completed

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor (RADIANT-2)

Carcinoid Tumor | Malignant Carcinoid Syndrome

France, Spain, Netherlands, United States, Canada, Sweden, Italy, Australia, Germany, Greece, Belgium, Czech Republic, Slovakia, Finland, United Kingdom
BeiGene

Recruiting

Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma (MCL)

United States, China, Israel, Belgium, Poland, Spain, Turkey, Brazil, Italy, Canada, United Kingdom, France, Germany, Argentina, Puerto Rico
Pfizer

Active, not recruiting

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Ovarian Cancer | NSCLC | Solid Tumors | Urothelial Cancer | Advanced Malignancies

Hungary, Spain, United States, Canada, Taiwan, Japan, Serbia, Italy, New Zealand, Australia, Mexico, Russian Federation, United Kingdom, France, Korea, Republic of, Belgium, Poland, Denmark, Israel
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Avelumab Program Rollover Study

Solid Tumors

Korea, Republic of, United States, Spain, United Kingdom, Russian Federation, Argentina, Australia, Italy, Japan, Belgium, Brazil, Czechia, France, Germany, Hungary, Romania, Turkey, Bulgaria, Mexico, Poland, Thailand, Ukraine
National Cancer Institute (NCI)

Terminated

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

High Grade Sarcoma | Metastatic Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Leiomyosarcoma | Myxofibrosarcoma | Metastatic Malignant Peripheral Nerve Sheath Tumor | Metastatic Synovial Sarcoma | Metastatic Undifferentiated... and other conditions

United States
Amgen

Completed

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ARROW2)

Relapsed or Refractory Multiple Myeloma

France, Czechia, Sweden, United States, Greece, Spain, Finland, Romania, Germany, Japan, Netherlands, Turkey, Austria, Bulgaria, Lithuania, Russian Federation, Slovakia
National Cancer Institute (NCI)

Recruiting

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Glioblastoma | Malignant Glioma | Anaplastic Astrocytoma | Anaplastic Astrocytoma, Not Otherwise Specified | Anaplastic Ganglioglioma | Anaplastic Pleomorphic Xanthoastrocytoma | WHO Grade 3 Glioma

United States, Puerto Rico
MacroGenics

Recruiting

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Recurrent | Immunotherapy | Androgen-Independent Prostatic Cancer | Androgen-Resistant Prostatic Cancer | Hormone Refractory Prostatic Cancer | Immune Checkpoint Inhibitor | Androgen-Independent Prostatic Neoplasms | Androgen-Insensitive Prostatic Cance | Inhibitory Checkpoint Molecule

United States, Spain, France, Belgium, United Kingdom, Poland, Georgia, Bulgaria, Puerto Rico, Australia
Alexion Pharmaceuticals

Completed

Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis

Refractory Generalized Myasthenia Gravis

Italy, United Kingdom, Spain, Belgium, Turkey, Japan, United States, Netherlands, Korea, Republic of, Argentina, Hungary, Sweden, Denmark, Brazil, Czechia, Finland, Canada
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

Recurrent Ovarian Carcinoma | Malignant Ovarian Clear Cell Tumor

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Malignant Solid Neoplasm | Nasopharyngeal Carcinoma | Adenoid Cystic Carcinoma | Transitional Cell Carcinoma | Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | Chordoma | Gestational Trophoblastic Tumor | Pseudomyxoma Peritonei | Cervical Adenocarcinoma | Vaginal Adenocarcinoma | Vaginal Squamous Cell... and other conditions

United States, Guam
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology

Completed

Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Novartis Pharmaceuticals

Completed

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus)

Malignant Melanoma

Canada, Italy, Czechia, Australia, France, Greece, Israel, Russian Federation, Sweden, United Kingdom, Hungary, Slovakia, Slovenia, Japan, Turkey, Argentina, Finland, Norway, Brazil, Latvia, Lithuania, Poland, Portugal
Amgen

Recruiting

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301)

Solid Tumors

Canada, Korea, Republic of, Australia, Netherlands, United States, Israel, Austria, Spain, United Kingdom, France, Belgium, Japan, Czechia, Hungary, Poland, Brazil, Italy, Argentina, Denmark, Greece, Mexico, Switzerland, Romania, Finland and more
NRG Oncology
National Cancer Institute (NCI)

Completed

Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery

Fallopian Tube Carcinoma | Endometrial Serous Adenocarcinoma | Ovarian Carcinoma | Malignant Female Reproductive System Neoplasm | Primary Peritoneal Carcinoma | Stage IIIA Uterine Corpus Cancer AJCC v7 | Stage IIIB Uterine Corpus Cancer AJCC v7 | Stage IIIC Uterine Corpus Cancer AJCC v7 | Stage IVA... and other conditions

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Endometrial Adenocarcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma | Gastrointestinal Complication and other conditions

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

Solid Tumors

United States, Korea, Republic of, Taiwan, France, United Kingdom, Belgium, Czechia, Germany, Poland
National Cancer Institute (NCI)

Suspended

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma

United States
Alexion Pharmaceuticals

Completed

Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)

Refractory Generalized Myasthenia Gravis

Korea, Republic of, United States, Spain, Canada, Netherlands, Belgium, Czechia, Denmark, Italy, Australia, Finland, Turkey, Germany, Greece, Brazil, Argentina, Japan, United Kingdom, Hungary, France, Sweden
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumor | Metastatic Malignant Neoplasm in the Liver | Stage I Pancreatic Neuroendocrine Tumor AJCC v8 | Stage II Pancreatic Neuroendocrine Tumor AJCC v8 | Stage III Pancreatic Neuroendocrine Tumor AJCC v8

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Recurrent Osteosarcoma | Refractory Osteosarcoma | Stage IV Osteosarcoma AJCC v7 | Stage IVA Osteosarcoma AJCC v7 | Stage IVB Osteosarcoma AJCC v7 | Metastatic Osteosarcoma

United States, Canada, Puerto Rico
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell Carcinoma | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm

United States
Seagen Inc.

Terminated

Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

Follicular B-cell Non-Hodgkin's Lymphoma | Diffuse Large B-cell Lymphoma Refractory

United States, Italy, Spain, United Kingdom, Czechia, Poland, France
SWOG Cancer Research Network
National Cancer Institute (NCI); Gilead Sciences

Recruiting

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Metastatic Malignant Neoplasm in the Brain | Metastatic HER2 Negative Breast Carcinoma

United States
Celgene

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)

Relapsed or Refractory Multiple Myeloma

United States, Australia, Italy, China, Spain, Germany, Romania, Korea, Republic of, Japan, United Kingdom, Czechia, Finland, France, Greece, Argentina, Belgium, Austria, Portugal, Israel, Poland, Brazil, Turkey, Canada, Ireland, New Zealand and more
Celgene

Completed

Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function (RENAL)

Multiple Myeloma | Non-Hodgkin's Lymphoma | AML | Solid Tumors | MDS | Hodgkin's Disease

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Prostate Adenocarcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

United States, Canada
BeiGene

Recruiting

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY)

Marginal Zone Lymphoma | Relapsed/Refractory Follicular Lymphoma

United States, Italy, Spain, China, United Kingdom, Australia, Israel, Korea, Republic of, France, Brazil, Ireland, Czechia, Romania, Argentina, Puerto Rico, Austria
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Recurrent Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Metastatic Malignant Neoplasm in the Brain | Stage IV Breast Cancer AJCC v6 and v7 | Metastatic Breast Carcinoma | Metastatic BRCA-Associated Breast Carcinoma

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Unresectable Melanoma

United States
National Cancer Institute (NCI)

Recruiting

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7

United States
K-Group, Beta, Inc., a wholly owned subsidiary...

Recruiting

A Study of ZN-c3 in Patients With Ovarian Cancer

Fallopian Tube Cancer | Solid Tumor | Epithelial Ovarian Cancer | Peritoneal Cancer

United States, Australia, Bulgaria, Bosnia and Herzegovina, Georgia, Korea, Republic of, Serbia
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Osteosarcoma | Lymphoblastic Lymphoma | Recurrent Lymphoma | Recurrent Malignant Neoplasm | Hodgkin Lymphoma in Remission | Leukemia in Remission | Recurrent Leukemia

United States, Australia, Canada, Puerto Rico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Cancer Research UK; European Organisation for... and other collaborators

Active, not recruiting

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Seminoma | Teratoma | Choriocarcinoma | Germinoma | Germ Cell Tumor | Yolk Sac Tumor | Mixed Germ Cell Tumor | Childhood Teratoma | Malignant Germ Cell Neoplasm | Extragonadal Seminoma | Non-seminomatous Germ Cell Tumor

United States, Germany, France, Spain, Netherlands, Australia, Belgium, Switzerland, United Kingdom, Italy, Denmark, Ireland
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

Cardiotoxicity | Recurrent Breast Carcinoma | HER2/Neu Positive | Metastatic Malignant Neoplasm in the Brain | Stage IV Breast Cancer AJCC v6 and v7

United States, Korea, Republic of, Puerto Rico, Saudi Arabia
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Metastatic Melanoma | Recurrent Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Alveolar Rhabdomyosarcoma | Embryonal Rhabdomyosarcoma | Botryoid-Type Embryonal Rhabdomyosarcoma | Spindle Cell Rhabdomyosarcoma | Spindle Cell/Sclerosing Rhabdomyosarcoma | Metastatic Embryonal Rhabdomyosarcoma | Metastatic Rhabdomyosarcoma | Solid Alveolar Rhabdomyosarcoma

United States, Canada, Australia, Puerto Rico, Saudi Arabia
Incyte Corporation

Active, not recruiting

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Cervical Cancer | Nasopharyngeal Carcinoma | Advanced Solid Tumors | Mesothelioma | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Anal Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1) | Urothelial... and other conditions

Finland, United States, United Kingdom, Belgium, Sweden, Denmark, Norway
National Cancer Institute (NCI)

Recruiting

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Glioblastoma | Malignant Glioma | Anaplastic Astrocytoma | Anaplastic Astrocytoma, Not Otherwise Specified | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | Glioblastoma, Not Otherwise Specified

United States, Australia, New Zealand, Canada
American Society of Clinical Oncology
Bristol-Myers Squibb; Eli Lilly and Company; Bayer; Merck Sharp & Dohme LLC; Pfizer; AstraZene... and other collaborators

Recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)

Lymphoma, Non-Hodgkin | Multiple Myeloma | Advanced Solid Tumors

United States
National Cancer Institute (NCI)

Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

Malignant Solid Neoplasm | Acute Myeloid Leukemia | Multiple Myeloma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer... and other conditions

United States, Puerto Rico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Pain | Urinary Complications | Breast Adenocarcinoma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | Metastatic Malignant Neoplasm to the Bone | Musculoskeletal Complication

United States, Puerto Rico
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer

Lymphoma | Unspecified Adult Solid Tumor, Protocol Specific | Cachexia | Lymphoproliferative Disorder

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Carcinoid Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic Digestive... and other conditions

United States

Clinical Trials on Refractory Malignant Solid Neoplasm in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations